Myeloma BioBank
Myeloma BioBank
At the Institute for Myeloma & Bone Cancer Research (IMBCR)
An Institute for Myeloma & Bone Cancer Research (IMBCR) Company
YOU have WHAT?
The companion book to I have WHAT? is now available for purchase. It is a helpful resource for caregivers as well as patients and their families.
I have WHAT?
The companion book to YOU have WHAT? is now available for purchase. It is a helpful resource for caregivers as well as patients and their families.
EVENT
Join us in our celebration of life and learn how you can help IMBCR continue to “make the impossible, possible” to extend the lives of patients.
At IMBCR, we have boldly set out to reimagine therapeutic approaches and patient monitoring strategies for multiple myeloma.
We focus on the individual needs of patients, not just treatment, but all-encompassing care. Collaborating with centers of excellence and industry leaders globally, we explore available drugs, novel agents, and new targets. These efforts will help to determine optimal and personalized treatments to maximize their benefits for each patient. IMBCR’s published research provides the gateway to transformative therapies resulting in superior outcomes. This has resulted in patients receiving advanced precision care and extending their life expectancy.
Patients with multiple myeloma want to know their physician is giving them the best care possible.
Patients are focused on:
Today
IMBCR research enables clinicians to identify the disease faster, optimize treatment plans, and provide the most effective therapy available. See how IMBCR Initiatives are accomplishing this.
Precision Care
Quality of Life
PRECISION MYELOMA
By combining analysis of big data technologies, genetics, and patient medical and treatment history, Precision Myeloma empowers doctors to give personalized care leading to longer survival, better treatment tolerability and ultimately a cure.
Help us develop this exciting new project.
Living Life Free of Myeloma
Ultimately our goal is to eradicate myeloma and allow patients to continue to Live Better and Live Longer. IMBCR!
CURE MYELOMA PROJECT
Multiple myeloma is a rare blood cancer of malignant cells found in the bone marrow that has had many therapeutic breakthroughs in the past decade; and, as a result, has become perhaps the most complicated cancer to treat and manage.
You Can Help
The Institute for Myeloma & Bone Cancer Research (IMBCR), formed in 2003, is dedicated to advance the treatment of myeloma by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care.
It is through the support of our donors that IMBCR is able to reimagine drug development strategies for multiple myeloma and determine optimal and personalized combinations to maximize their benefits for patients.
We are dedicated to making the impossible possible so that all patients with myeloma to Live better. Live Longer. IMBCR!
Dr. James R. Berenson, a global innovative thought leader in multiple myeloma, formed the Institute for Myeloma & Bone Cancer Research (IMBCR) in 2003. This offers scientists the opportunity to work in an unencumbered environment to explore new directions in a state of the art, self-contained laboratory facility. IMBCR is a team of dedicated scientists with extensive expertise in cancer research, particularly in the fields of myeloma, metastatic bone cancer, genetics, immunology, and tumor microenvironment. They use models of myeloma and other bone cancers to make groundbreaking discoveries that have led to many new treatments for these diseases and ways to monitor them.
